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in the antimelanogenic action down-
regulating the expression of MITF or
tyrosinase gene in cAMP-elevated mela-
nocyte cultures and UV-irradiated dor-
sal skins of guinea pigs (Supplementary
Figure S12 online). Finally, this study
suggests a potential application of
4H3MC in the treatment of hyperpig-
mented skin disorders.
Animal experiments were carried out
according to the protocols approved by
Animal Experimentation Ethics Commit-
tee in CBNU institute.
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TO THE EDITOR
Among the several characteristics of
malignant melanoma, insensitivity to
anti-cancer agents is a frequent clinical
problem in the treatment of patients
(Grossman and Altieri, 2001). In fact,
the most commonly used chemotherapy
agents cisplatin and dacarbazine for
malignant melanoma elicit a response
rate of only 10% (Flaherty, 2010).
The small-molecule inhibitor of
BRAF, vemurafenib (also known as
PLX4032), elicits potent tumor regres-
sion in patients with BRAF-positive stage
IV melanoma (Huang et al., 2012), and
its use is expected in patients harboring
the BRAFV600E mutation (Tsai et al.,
2008). However, vemurafenib is not
effective against melanomas with wild-
type BRAF protein (Joseph et al., 2010).
Acral lentiginous melanoma (ALM) is
one of the subtypes of cutaneous mela-
noma most frequent in colored races
(Bradford et al., 2009). In fact, only
about 10% of ALM cases harbor the
BRAFV600E mutation, compared with
over 60% of cases of superficial spread-
ing melanoma (SSM), which is most fre-
quent in Caucasian populations (Saldanha
et al., 2006). Because these melanomas
are insensitive to BRAF inhibitors (Joseph
et al., 2010), a search for molecular
targets that would enhance sensitivity to
standard treatment with cisplatin or
dacarbazine would seem justified.
To address the genes responsible for
drug resistance in melanoma, whole-
exome sequencing was performed. We
identified a single-nucleotide deletion in
codon 507 from exon 4 of the KEAP1
gene, common to MM-RU and PM-WK,
as a candidate gene for drug resistanceAccepted article preview online 12 August 2013; published online 19 September 2013
Abbreviations: ALM, acral lentiginous melanoma; CDDP, cis-diamminedichloro-platinum (II); DTIC, 5-(3,
3-dimethyl-1-triazenyl) imidazole-4-carboxamide; FSM, frameshift mutant; ROS, reactive oxygen species;
SSM, superficial spreading melanoma
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(Figure 1a). The KEAP1 protein pro-
duced by this mutant allele partially
lacks the DGR/Kelch domain that is
important for interacting with NRF2, a
key transcriptional regulator of oxidative
stress such as that resulting from reactive
oxygen species (ROS; Figure 1b). Under
normal conditions, NRF2 is kept tran-
scriptionally inactive through binding
to the DGR domains of KEAP1 and
constitutively degraded by the ubiquitin
proteasome system (Sekhar et al., 2002).
In contrast, in the cell lines harbor-
ing the KEAP1 frameshift mutation
(KEAP1-FSM), constitutive NRF2 stabili-
zation, nuclear localization (Supple-
mentary Figure S1 online), and target-
gene activation were observed
(Supplementary Figure S2 online). We
also observed strong expression of the
NRF2 protein in HMVI cells, which do
not harbor KEAP1 mutation, suggesting
that another signaling pathway, such
as the PI3K pathway, may regulate the
constitutive expression of NRF2 in
HMVI cells (Mitsuishi et al., 2012).
Thus far, several somatic mutations of
KEAP1 that affect its NRF2-inhibitory
activity have been identified in patients
with cancers of the lungs, gallbladder,
and liver (Taguchi et al., 2011). Aberrant
activation of NRF2 induced by KEAP1
gene mutation in gallbladder cancer has
been reported to lead to 5-fluorouracil
(5-FU) resistance (Shibata et al., 2008).
However, the relationship between the
KEAP1-NRF2 pathway and drug resis-
tance in malignant melanoma still
remains to be elucidated.
Cisplatin (cis-diamminedichloro-plati-
num (II), CDDP) and dacarbazine (5-(3,
3-dimethyl-1-triazenyl) imidazole-4-car-
boxamide, DTIC) have been shown to
increase oxidative stress by raising the
levels of intracellular ROS such as H2O2
(Zhang et al., 2010; Deavall et al.,
2012). Therefore, we investigated
whether NRF2 is involved in sensitivity
to these drugs. The ratio of reduced-to-
oxidized glutathione (GSH/GSSG) was
decreased by treatment with CDDP or
DTIC in siNRF2-transfected PM-WK
cells (Figure 1c and d). Furthermore,
intracellular ROS levels were increased
by treatment with CDDP or DTIC in
siNRF2-transfected cells, suggesting that
the H2O2 detoxification pathway is
active in these cell lines (Figure 1e;
Supplementary Figure S3a online).
Notably, knockdown of NRF2 by small
interfering RNA in PM-WK and MM-RU
cells significantly enhanced their sensi-
tivity to apoptosis by CDDP or DTIC
(Figure 1f; Supplementary Figures S3b
and S4 online). Conversely, the over-
expression of NRF2 or activation of
NRF2 by sulforaphane in G-361 cells
reduced their sensitivity to CDDP or
DTIC (Supplementary Figure S5
online). Moreover, the NRF2-positive
cell lines tended to show higher IC50
values compared with NRF2-negative
cell lines (Supplementary Figure S6
online). Taken together, the data indi-
cate that, in addition to the mechanisms
of drug resistance in melanoma, such as
drug trapping by melanosomes and
elevated expression of ATP-dependent
transporters (Gottesman et al., 2002;
Chen et al., 2006), aberrantly expre-
ssed NRF2 is one of the causes of
resistance to CDDP and DTIC.
Next, we examined KEAP1 gene
mutation and NRF2 expression in speci-
mens of primary melanoma. The histo-
logical types, patient genders and ages,
and the stages of the primary melano-
mas we examined are shown in Supple-
mentary Table online. Ten (48%), eight
(38%), two (10%), and one (4%) of the
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Figure 1. NRF2 contributes to chemoresistance in KEAP1-FSM cells. (a) Representative
electrophoretograms of KEAP1 gene exon 4 by capillary sequencing in melanoma cell lines. Arrowheads
indicate the single-nucleotide deletion at codon 507 (1518delC). (b) Schematic representation of the
KEAP1 protein. Arrowheads indicate the appearance of a stop codon. (c) Expression of NRF2 protein in
siCtrl- or siNRF2-transfected PM-WK cells. (d) Quantification of the ratio of reduced-to-oxidized
glutathione (GSH/GSSG) or (e) intracellular reactive oxygen species levels after treatment with vehicle,
CDDP, or DTIC in siCtrl- or siNRF2-transfected PM-WK cells. (f) Cell viability at 24 hours after treatment
with vehicle, CDDP, or DTIC in siCtrl- or siNRF2-transfected PM-WK cells. NS, no significant
difference; *Po0.05 and **Po0.01 versus control by t-test. CDDP, cis-diamminedichloro-platinum
(II); DTIC, 5-(3, 3-dimethyl-1-triazenyl) imidazole-4-carboxamide.
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21 cases were ALM, NM, LMM, and
SSM, respectively. We performed direct
sequencing of KEAP1 gene exon 4 using
the genomic DNAs extracted from these
paraffin-embedded specimens. In two of
the 21 cases (B10%), we identified a
homozygous single-nucleotide deletion
that was the same as that identified
in melanoma cell lines (#02-2078,
1518delC) and a heterozygous single-
nucleotide deletion in a neighboring
position (#03-8008, 1519delG) (Supple-
mentary Table online). The stop codon
appeared 23 nucleotides after the
1519delG mutation and also produced
the same type of truncated KEAP1 pro-
tein as that resulting from 1518delC
mutation. Immunohistochemical stain-
ing revealed that NRF2 was positive in
specimens #02-2078 and #03-8008
(Figure 2b and d, respectively), which
were ALM specimens harboring KEAP1-
FSM mutation, whereas NRF2 was
negative in specimens #09-7356 and
#07-7252, which were ALM specimen
without KEAP1 mutation (Figure 2,
Supplementary Table online). We also
performed direct sequencing of BRAF
gene exon 15 using DNAs from
#02-2078, #03-8008, #08-6115, and
#09-7356, but the typical BRAFV600E
mutation was not identified (Supple-
mentary Table online). Taking these
results together, it appears that the loss
of function of KEAP1 caused by single-
nucleotide deletions is indeed corre-
lated with aberrant NRF2 expression in
primary melanoma.
Missense mutations of the KEAP1
gene have been identified in various
cancers. Interestingly, the KEAP1-FSMs
are most frequently identified in the
DGR domain (65%), which is important
for interaction with NRF2 (Taguchi
et al., 2011). Our results also indicate
that the DGR domain of the KEAP1 gene
may be a ‘‘hot-spot’’ for FSM that causes
aberrant activation of NRF2 and causes
melanomas to become more resistant to
CDDP or DTIC.
In conclusion, our present results
and available data fully support the
possibility that decreased expression or
inhibition of NRF2 may provide an
avenue for treatment of patients with
malignant melanoma, by improving the
rate of response to the standard che-
motherapy agents, namely, cisplatin and
dacarbazine.
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TO THE EDITOR
The aryl hydrocarbon receptor (AhR)
is a ligand-activated transcription factor
that mediates the toxicity of 2,3,7,
8-tetrachlorodibenzo-p-dioxin (TCDD),
polycyclic aromatic hydrocarbons, and
related environmental contaminants
(Abel and Haarmann-Stemmann, 2010).
The unligated AhR is trapped in a
cytosolic multiprotein complex, which
rapidly dissociates upon ligand binding.
Subsequently, the AhR shuttles into the
nucleus, dimerizes with ARNT, and
binds to xenobiotic-responsive elements
(XREs) in the promoter of target genes,
e.g., encoding cytochrome P450 (CYP) 1
monooxygenases, to enforce transcrip-
tion (Abel and Haarmann-Stemmann,
2010). Furthermore, AhR-triggered acti-
vation of c-src tyrosine kinase stimulates
EGFR and downstream mitogen-acti-
vated protein kinase signaling, resulting
in the induction of XRE-independent
genes, such as cyclooxygenase-2 (COX-2;
Abel and Haarmann-Stemmann, 2010).
We have previously shown that the
AhR in keratinocytes is not only activa-
ted by anthropogenic chemicals but also
by UVB irradiation, which leads to the
intracellular formation of the tryptophan
photoproduct and high-affinity AhR
ligand 6-formylindolo[3,2-b]carbazole
(FICZ; Rannug et al., 1995; Fritsche
et al., 2007). Indeed, UVB exposure en-
hances AhR/XRE binding (Supplemen-
tary Figure 1 online) and accompanied
CYP1A1/1B1 expression (Katiyar et al.,
2000), as well as XRE-independent
COX-2 expression (Fritsche et al.,
2007).
Because (i) overexpression of a con-
stitutively active AhR causes inflamma-
tory skin lesions (Tauchi et al., 2005),
(ii) an increase in CYP activity leads to
reactive oxygen species formation
(Puntarulo and Cederbaum, 1998), (iii)
CYP1 enzymes are critical for chemical-
induced skin carcinogenesis (Shimizu
et al., 2000), and (iv) COX-2 is
involved in UV-induced inflammation
and carcinogenesis (Elmets et al., 2010),
it was postulated that a transient inhi-
bition of AhR may protect human skin
against the detrimental effects of UVB
irradiation (Agostinis et al., 2007;
Haarmann-Stemmann et al., 2012).
Moreover, we have shown that the
expression of matrix metalloproteinase-
1 (MMP-1), which is critically involved
in extrinsic skin aging, is upregulated in
an AhR-dependent manner in tobacco
smoke extract–exposed keratinocytes
(Ono et al., 2013). Therefore, we deci-
ded to develop an AHR antagonist that
is suitable for topical UV-protection.
We screened a library of compounds
that possess the structural prerequisites to
Accepted article preview online 30 August 2013; published online 10 October 2013
Abbreviations: AhR, aryl hydrocarbon receptor; BDDI, E/Z-2-benzylidene-5,6-dimethoxy-3,3-
dimethylindan-1-one; COX-2, cyclooxygenase-2; CYP, cytochrome P450; EROD, 7-O-ethoxyresorufin-
deethylase; FICZ, 6-formylindolo[3,2-b]carbazole; MMP-1, matrix metalloproteinase-1; MNF, 30-methoxy-
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